RxDoctor Payments Data

Sean Liston, MD

Ophthalmology · Chico, CANPI 1104036128

Payments from drug & device makers

$5,309in general payments, 2019–2025

Across 113 payments — averaging $46.99 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Rxsight Inc$3K
  • Alcon$300
  • AbbVie$287
  • Johnson & Johnson Surgical Vision, Inc.$272
  • Glaukos Corporation$232
  • Amgen$217
  • plus $959 from 15 others

What the payments were for

  • Consulting fees$2,77852%
  • Food & beverage$2,53248%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,309 in reported general payments places this provider in the 75th percentile of 2,513 ophthalmology providers in California.

See all ophthalmology providers in California

Medicare billing

Part B allowed, 2024
$621,980
Medicare patients
1,399
Services billed
6,627

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LumiganBimatoprost62$26,443
RestasisCyclosporine20$25,811
XiidraLifitegrast13$20,039
RhopressaNetarsudil Mesylate26$14,845
CombiganBrimonidine Tartrate/Timolol58$13,945
ProlensaBromfenac Sodium36$12,312
RocklatanNetarsudil Mesylat/Latanoprost13$11,637
Fluorometholone146$10,729
Cyclosporine12$9,592
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol57$8,672
FlarexFluorometholone Acetate41$6,223
SimbrinzaBrinzolamide/Brimonidine Tart27$5,715
Prednisolone Acetate131$5,137
Alphagan PBrimonidine Tartrate14$4,329
Latanoprost318$3,972

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLumigan, Restasis, Combigan, Alphagan P$287$70,529154 claims
Aerie Pharmaceuticals, Inc.Rhopressa, Rocklatan$189$26,48239 claims
Bausch & Lomb Americas Inc.Xiidra$31$20,03913 claims
Bausch & Lomb, A Division Of Bausch Health US, LLCProlensa$21$12,31236 claims
Eyevance Pharmaceuticals LLCFlarex$47$6,22341 claims
AlconSimbrinza$300$5,71527 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 2,513 ophthalmology providers in California.

Other ophthalmology in Chico

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →